详细信息

TRPV1介导神经源性炎症介质调控变应性鼻炎的研究进展    

Progress in the Modulation of Allergic Rhinitis Through TRPV1-mediated Neurogenic Inflammatory Mediators

文献类型:期刊文献

中文题名:TRPV1介导神经源性炎症介质调控变应性鼻炎的研究进展

英文题名:Progress in the Modulation of Allergic Rhinitis Through TRPV1-mediated Neurogenic Inflammatory Mediators

作者:全苹[1];赵跃[1];王志旺[1];张悦[1];任远[1];段海婧[1];程小丽[2]

第一作者:全苹

机构:[1]甘肃中医药大学药学院,兰州730000;[2]甘肃中医药大学教学实验实训中心,兰州730000

第一机构:甘肃中医药大学药学院(西北中藏药协同创新中心办公室)

年份:2026

卷号:43

期号:1

起止页码:155

中文期刊名:中国现代应用药学

外文期刊名:Chinese Journal of Modern Applied Pharmacy

收录:;北大核心:【北大核心2023】;

基金:国家自然科学基金项目(82260852、81460668);甘肃省自然科学基金项目(20JR5RA183、1606RJZA011、1310RJZA086)。

语种:中文

中文关键词:变应性鼻炎;瞬时感受器电位香草酸受体1;神经肽;神经营养素;神经源性炎症

外文关键词:allergic rhinitis;transient receptor potential vanilloid receptor 1(TRPV1);neuropeptide;neurotropin;neurogenic inflammation

摘要:变应性鼻炎(allergic rhinitis,AR)是一种常见的鼻腔免疫炎症性疾病,鼻黏膜免疫炎症反应是其基础病理学特征。瞬时感受器电位香草酸受体1(transient receptor potential vanilloid receptor 1,TRPV1)是一种非选择性阳离子通道,其兴奋后可引起P物质、降钙素基因相关肽以及血管活性肠肽等神经源性炎症介质释放,共同参与调控神经源性炎症反应。近年来研究发现,TRPV1及其介导的神经源性炎症介质对AR及其病理学反应有明显调控作用,本文就TRPV1介导的神经源性炎症介质在AR中的研究进展进行综述,为AR的基础研究与新药研发提供理论依据。
Allergic rhinitis(AR)is a prevalent immune-mediated inflammatory disorder of the nasal cavity,immuneinflammatory response in the nasal mucosa as it fundamental pathological feature.Transient receptor potential vanilloid receptor 1(TRPV1)as a non-selective cation channel,upon activation,triggers the release of neurogenic inflammatory mediators such as substance P(SP),calcitonin gene-related peptide(CGRP),and vasoactive intestinal peptide(VIP),among others,these mediators collectively contribute to the modulation of neurogenic inflammation.Recent studies have demonstrated that TRPV1 and its associated neurogenic inflammatory mediators exert significant regulatory effects on AR and its pathological manifestations.This review aims to summarize the advancements in research regarding TRPV1-mediated neurogenic inflammatory mediators in AR,thereby providing a theoretical foundation for both basic research and novel drug development targeting AR.

参考文献:

正在载入数据...

版权所有©甘肃中医药大学 重庆维普资讯有限公司 渝B2-20050021-8 
渝公网安备 50019002500408号 违法和不良信息举报中心